At TCT 2008, Datascope Corp. highlighted its Sensation 7 Fr. inter-aortic balloon catheter and the CS300 IABP with IntelliSense, which combine fiber-optic speed with automatic in vivo calibration for faster time to therapy, faster signal acquisition, and faster adaptation to rate and rhythm changes.

At TCT 2008 AGA Medical Corp. highlighted its self-expanding AMPLATZER Muscular VSD Occluder for complex ventricular septal defect (VSD) repair in patients considered to be high-risk for standard transatrial or transarterial surgical repair.

FlowCardia Inc., a medical device company developing a portfolio of endovascular devices for the treatment of coronary and peripheral chronic total occlusions (CTOs), highlighted its CROSSER 14P, CROSSER 14S and CROSSER 18 CTO Recanalization Catheters at TCT 2008.

Vascular Solutions' Jiffy Wire, an 80 cm 0.035-inch specialty guide wire, was launched in July 2008 and was featured at TCT 2008.

The Jiffy Wire offers the benefits of both a straight floppy tip and a 3 mm J-tip in one double-ended guide wire. The 80 cm working length and stiff shaft of the Jiffy Wire provides control and eases wire manipulation for access procedures, while the 10 cm graduated transition tips facilitate atraumatic access and device placement, the company said. The coils of the Jiffy Wire are pre-coated with a smooth PTFE coating.

October 2008

The Cordis Aquatrack Hydrophilic Guide Wire is designed to facilitate access to the most tortuous anatomy.

The Ostial Pro Stent Positioning System is designed to facilitate precise stent implantation in coronary and renal aorto-ostial lesions, eliminating the guesswork when deploying a stent at the “true” ostium of the vessel.

Morris Innovative offers the FISH (Femoral Introducer Sheath and Hemostasis) Device that combines one sheath as both an introducer and closure device.

October 17, 2008 - Elixir Medical Corp. today announced results from three multicenter first-in-man studies of Novolimus and Myolimus eluting coronary stent systems at the 20th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

October 17, 2008 - Boston Scientific Corp. announced results at TCT from an analysis of the HORIZONS-AMI trial showing a 41 percent reduction in revascularization in patients with TAXUS Express Paclitaxel-eluting coronary stents as opposed to those with non-drug-eluting Express stents.

October 17, 2008 - The Medicines Company’s Angiomax (bivalirudin) significantly reduced cardiac-related death, improved overall survival and reduced major bleeding compared to conventional therapy (heparin plus a platelet glycoprotein IIb/IIIa inhibitor) in patients undergoing angioplasty for up to one year, according to data released at TCT this week from the HORIZONS-AMI study.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now